Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$315.3MCash on Hand
26mo Cash Runway
Follow BBOT by emailGet an email when BBOT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BBOT, unsubscribe in one click. Privacy
📣 What BBOT Says Is Next
fourth quarter of 2026 · “Monotherapy data update expected in the fourth quarter of 2026.”
Company press release, Nov 10, 2026 · SEC filing
fourth quarter of 2026 · “Monotherapy data update expected in the fourth quarter of 2026 BBO-10203: An orally bioavailable small molecule with a novel mechanism of action designed to block the physical interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors.”
Company press release, Nov 10, 2026 · SEC filing
mid-2027 · ““With a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.” Key Program Highlights and Updates BBO-8520: An orally bioavailable small molecule direct inhibitor targeting both the ON and OFF states of KRAS G12C .”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings BBOT reported Q3 2026 results: cash of $315.3 million, cash runway into 2029, and net loss of $34.2 million versus $44.8 million a year earlier. BBO-8520 plus pembrolizumab showed a 75% ORR at 500 mg QD in NSCLC. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Leadership Chief Medical and Development Officer Yong Ben, M.D., M.B.A. gave notice of resignation on October 30, 2026, effective January 8, 2027. The filing says the resignation was not due to any disagreement with the company. Form 8-K · SEC filing
Sep 8, 2026 ·
Clinical trial Announced new BBO-8520 data, with 75% ORR at 500 mg QD plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC (N=17 across doses: 53%). Monotherapy in naive patients showed 63% ORR (26/41). Cash was $344.1 million, with runway into 2028. Form 8-K · SEC filing · Press release
Sep 1, 2026 ·
Financing Shelf registration for up to $500,000,000 of common stock, preferred stock, debt securities, warrants or units, with up to $200,000,000 of common stock to be sold through a sales agreement with Leerink Partners and Cantor Fitzgerald. Amounts per offering are not yet set. Form S-3 · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 results: R&D expenses of $49.2 million versus $27.4 million a year earlier, G&A of $11.0 million versus $2.7 million, and a net loss of $56.5 million versus $28.4 million. Cash totaled $344.1 million, expected to fund operations into 2028. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
BBOT holds $315.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.4M/quarter from operations,
an estimated runway of 26 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:10 · Low
Cash runway 26 months
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Sep 2026) +10
Company says cash lasts into 2029 -15We estimate that our existing cash, cash equivalents, short-term marketable securities, and long-term marketable securities as of the date of this report will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Sep 1, 2026 · Shelf registration with ATM program, up to $200M · S-3
Share count 80,251,267 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BBOT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BBOT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.